Familial Hypercholesterolemia Heterozygous — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for familial hypercholesterolemia heterozygous. 39 active patents protecting 5 drugs from 4+ originators. First major cliff: 2037. Daily refresh.

5
Approved drugs
39
Active US patents
60/100
Avg vulnerability
—
Annual revenue covered

Originators in Familial Hypercholesterolemia Heterozygous

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Merck & Co. 18 patents Esperion Theraps Inc 15 patents Pfizer 5 patents Salix 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating familial hypercholesterolemia heterozygous. Each bar = one year. Y-axis scaled to peak year (10 patents).

6
26
2
27
4
30
9
33
3
36
5
37
10
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Nexletol
BEMPEDOIC ACID
 Esperion Theraps Inc 15 46 — 2030-12-03
Zocor
simvastatin
 Merck & Co. 10 70 — 2026-10-11
Zetia
EZETIMIBE
 Merck & Co. 8 63 — 2033-05-01
Lipitor
Atorvastatin Calcium
 Pfizer 5 61 — 2037-06-07
Tricor (Micronized)
FENOFIBRATE
 Salix 1 62 — 2033-05-31

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7326708 Zocor other 80 2026-10-11
7326708 Zocor other 80 2026-10-11
7326708 Zocor other 80 2026-10-11
7326708 Zocor other 80 2026-10-11
7326708 Zocor other 80 2026-10-11
7326708 Zocor other 80 2026-10-11
11744816 Nexletol method of use 75 2036-03-14
11925704 Lipitor method of use 75 2037-06-07
11926584 Nexletol method of use 75 2040-06-19
11926584 Nexletol method of use 75 2040-06-19

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7335799 Nexletol composition of matter 10 2030-12-03
7335799 Nexletol composition of matter 10 2030-12-03
11613511 Nexletol composition of matter 12 2040-06-19
11613511 Nexletol composition of matter 12 2040-06-19
12398087 Nexletol composition of matter 17 2040-06-19
12398087 Nexletol composition of matter 17 2040-06-19
9597289 Zocor formulation 48 2030-02-23
9597289 Zocor formulation 48 2030-02-23
11760714 Nexletol formulation 50 2040-06-19
11760714 Nexletol formulation 50 2040-06-19

Related